Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12606000216516
Ethics application status
Approved
Date submitted
30/05/2006
Date registered
31/05/2006
Date last updated
19/09/2024
Date data sharing statement initially provided
19/09/2024
Type of registration
Retrospectively registered

Titles & IDs
Public title
The Christchurch Heart Failure Registry
Scientific title
Neurohormonal activation in people admitted to hospital with heart failure: it's role as a marker of severity of heart failure, cardiac function, response to treatment and prognosis.
Secondary ID [1] 313007 0
nil known
Universal Trial Number (UTN)
Trial acronym
nil known
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Heart failure 1194 0
Condition category
Condition code
Cardiovascular 1279 1279 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
neurohormonal levels and their relationship to severity of heart failure, cardiac function, response to treatment and overall prognosis for 5 years following discharge from hospital for heart failure
Intervention code [1] 1079 0
None
Comparator / control treatment
No comparator.
Control group

Outcomes
Primary outcome [1] 1729 0
To document all heart failure admissions to Christchurch Hospital over a two and a half year period
Timepoint [1] 1729 0
From 1997 to 2000
Secondary outcome [1] 3085 0
To determine the relationship of neurohormonal activation to severity of heart failure, cardiac function, response to treatment and overall prognosis.
Timepoint [1] 3085 0
Measured over the subsequent 5 years.

Eligibility
Key inclusion criteria
All patients with heart failure as a primary or secondary diagnosis.
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Any patient unable to give informed consent.

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/12/1997
Actual
1/12/1997
Date of last participant enrolment
Anticipated
Actual
31/12/2002
Date of last data collection
Anticipated
Actual
1/07/2024
Sample size
Target
2500
Accrual to date
Final
2500
Recruitment outside Australia
Country [1] 323 0
New Zealand
State/province [1] 323 0

Funding & Sponsors
Funding source category [1] 1401 0
Government body
Name [1] 1401 0
Health Research Council of New Zealand
Country [1] 1401 0
New Zealand
Primary sponsor type
Government body
Name
Health Research Council of New Zealand
Address
Country
New Zealand
Secondary sponsor category [1] 1231 0
Charities/Societies/Foundations
Name [1] 1231 0
New Zealand National Heart Foundation
Address [1] 1231 0
Country [1] 1231 0
New Zealand

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 2753 0
Christchurch
Ethics committee address [1] 2753 0
Ethics committee country [1] 2753 0
New Zealand
Date submitted for ethics approval [1] 2753 0
Approval date [1] 2753 0
Ethics approval number [1] 2753 0
99/02/014

Summary
Brief summary
This study will collect data from all patients admitted to Christchurch Hospital with heart failure over 2.5 years. Information will be collected from each patient about his/her background medical condition, results of routine tests performed during their hospital admission including blood tests, chest x-ray and cardiac scans. In addition 2 extra blood tests will be performed to look at levels of hormones produced by the heart and other parts of the body in response to heart failure. The first test will be performed within 24 hours of hospital admission, and the second just prior to discharge.
We will follow the progress of each participant after discharge to keep a record of sunsequent readmissions or death during the 5 year period following discharge.
We will analyse the hormone tests and other information collected to determine whether these results enable us to predict the severity of heart failure, the response to treatment and the overall outcome/outlook fo people admitted to hospital with heart failure.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 35731 0
Prof Professor Richard Troughton
Address 35731 0
Department of Medicine Christchurch School of Medicine and Health Sciences PO Box 4345 Christchurch
Country 35731 0
New Zealand
Phone 35731 0
+6433640640
Fax 35731 0
Email 35731 0
Richard [email protected]
Contact person for public queries
Name 10268 0
Lorraine Skelton
Address 10268 0
Department of Medicine
Christchurch School of Medicine and Health Sciences
PO Box 4345
Christchurch
Country 10268 0
New Zealand
Phone 10268 0
+64 3 3641063
Fax 10268 0
+64 3 3641115
Email 10268 0
[email protected]
Contact person for scientific queries
Name 1196 0
Dr Richard Troughton
Address 1196 0
Department of Medicine
Christchurch School of Medicine and Health Sciences
PO Box 4345
Christchurch
Country 1196 0
New Zealand
Phone 1196 0
+64 3 3641116
Fax 1196 0
+64 3 3641115
Email 1196 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.